FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
Rhea-AI Summary
FibroBiologics (Nasdaq:FBLG) reported preclinical data for its psoriasis program CYPS317, using human dermal fibroblast (HDF) spheroids, presented at the 2026 Society for Investigative Dermatology meeting.
In psoriasis animal models, HDF spheroids reduced disease severity, prevented relapse, improved systemic safety versus single-cell HDFs, and showed targeted immunomodulation across key inflammatory pathways.
AI-generated analysis. Not financial advice.
Positive
- HDF spheroids reduced disease severity in imiquimod-induced psoriasis animal models
- Spheroids showed more favorable systemic safety profile versus single-cell HDF delivery
- Booster dosing of HDF spheroids sustained efficacy and prevented splenomegaly
- CYPS317 reduced PASI scores and normalized monocyte-to-lymphocyte ratios
- Spheroid treatment limited epidermal thickening and immune cell infiltration histologically
- Cytokine profiling suggested targeted immunomodulation rather than broad immune suppression
Negative
- Findings are limited to preclinical animal models, with no human data reported
News Market Reaction – FBLG
On the day this news was published, FBLG declined NaN%, reflecting a moderate negative market reaction. Argus tracked a peak move of +10.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed moves: in the momentum scan, names like AKTX were sharply up while CRIS was down, and core peers such as LIXT and NRXS were modestly higher. With no clear, uniform direction and FBLG flat pre-news, the setup appears company-specific rather than a sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 18 | Patent application | Positive | +3.8% | Filed provisional patent for oral fibroblast-based GI therapeutics platform. |
| May 11 | Program expansion | Positive | -14.7% | Advanced fibroblast treatment strategy targeting Hantavirus pulmonary syndrome. |
| May 05 | Shareholder letter | Positive | -3.6% | Outlined CYWC628 trial start, timelines, and broader preclinical pipeline plans. |
| May 04 | Preclinical data | Positive | -3.6% | Reported burn-wound spheroid data showing anti-inflammatory and healing effects. |
| May 04 | Clinical trial prep | Positive | -5.5% | Released first cGMP CYWC628 batch enabling Phase 1/2 DFU clinical trial. |
Recent history shows the stock often declining on otherwise positive development updates, with only one of the last five news events seeing a positive next-day move.
Over the past few months, FibroBiologics reported several fibroblast-based platform milestones, including a new GI-focused patent filing on May 18, 2026, Hantavirus program expansion on May 11, 2026, and initiation steps for lead DFU program CYWC628 in early May. Despite generally constructive news, four of five prior events saw negative 24-hour price reactions, suggesting a pattern of weak follow-through on positive announcements that frames today’s psoriasis preclinical data.
Market Pulse Summary
This announcement adds psoriasis-specific preclinical evidence to FibroBiologics’ fibroblast spheroid platform, showing reduced disease severity, improved PASI scores, and histologic protection against epidermal thickening in animal models. Compared with recent updates in burns and diabetic foot ulcers, it reinforces a multi-indication strategy built on targeted immunomodulation. With shares around $1.05 and far below the 52‑week high of $19.8, investors may watch for clinical trial initiation, future data quality, and capital structure developments.
Key Terms
psoriasis medical
IL-23/Th17 axis medical
PASI scores medical
monocyte-to-lymphocyte ratios medical
epidermal thickening medical
immune cell infiltration medical
cytokine profiling medical
immunomodulation medical
AI-generated analysis. Not financial advice.
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with chronic psoriatic disease
HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced preclinical data from its CYPS317 program for psoriasis presented at the Society for Investigative Dermatology 2026 Annual Meeting, held May 13-15, 2026, in Chicago, Illinois. A link to the poster can be found here.
Psoriasis is a chronic inflammatory skin disease driven by dysregulated innate and adaptive immunity, with the IL-23/Th17 axis playing a central role in sustaining disease activity. In an imiquimod-induced psoriasis mouse model, both HDF spheroids and single-cell HDF preparations reduced disease severity; however, spheroids provided a more favorable systemic safety profile by avoiding the innate immune activation observed with single-cell delivery, an important distinction for a cell-based therapy intended for systemic administration.
In a chronic-relapsing psoriasis model, booster dosing of HDF spheroids sustained therapeutic efficacy and prevented splenomegaly, a marker of systemic immune burden. Additionally, CYPS317 demonstrated significant reductions in PASI scores, normalization of monocyte-to-lymphocyte ratios, and reduced splenic immune cell accumulation. Histological analyses confirmed that spheroid-treated animals were protected against epidermal thickening and immune cell infiltration, two hallmarks of active psoriatic disease. Cytokine profiling across disease stages demonstrated that single and multiple doses of HDF spheroids differentially regulated key inflammatory mediators, consistent with targeted immunomodulation rather than broad immune suppression.
“Our preclinical data reinforce the significant potential of a cell-based therapeutic for psoriasis and the importance of targeted immune modulation,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “Our fibroblast spheroid-based therapeutics have demonstrated durable immunomodulation across several chronic disease models. We believe these findings meaningfully strengthen the foundation for CYPS317 as a differentiated therapeutic approach for patients living with psoriasis.”
For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the significant potential of a cell-based therapeutic for psoriasis, the potential of FibroBiologics’ novel fibroblast technology, and the potential indications for FibroBiologics’ programs. These forward-looking statements are based on FibroBiologics’ management’s current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics’ management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption “Risk Factors” and elsewhere in FibroBiologics’ annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC’s website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics’ liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; and (c) the unpredictable relationship between R&D and preclinical results and clinical study results. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
